The stock of Dermira Inc (NASDAQ:DERM) is a huge mover today! The stock increased 3.58% or $1.21 during the last trading session, hitting $35.03. About 356,260 shares traded hands or 70.12% up from the average. Dermira Inc (NASDAQ:DERM) has risen 46.66% since February 29, 2016 and is uptrending. It has outperformed by 34.44% the S&P500.
The move comes after 7 months positive chart setup for the $1.28B company. It was reported on Oct, 4 by Barchart.com. We have $53.95 PT which if reached, will make NASDAQ:DERM worth $691.20M more.
Analysts await Dermira Inc (NASDAQ:DERM) to report earnings on November, 8. They expect $-0.64 earnings per share, down 10.34% or $0.06 from last year’s $-0.58 per share. After $-0.89 actual earnings per share reported by Dermira Inc for the previous quarter, Wall Street now forecasts -28.09% EPS growth.
Dermira Inc (NASDAQ:DERM) Ratings Coverage
Out of 4 analysts covering Dermira Inc (NASDAQ:DERM), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dermira Inc has been the topic of 8 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Needham on Friday, January 8. Citigroup maintained it with “Buy” rating and $40 target price in Wednesday, March 16 report. The stock of Dermira Inc (NASDAQ:DERM) earned “Buy” rating by Citigroup on Friday, December 18. The stock has “Buy” rating given by Needham on Wednesday, May 11. On Wednesday, August 19 the stock rating was initiated by Cowen & Co with “Outperform”.
According to Zacks Investment Research, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California.”
Insitutional Activity: The institutional sentiment increased to 2.78 in 2016 Q2. Its up 1.10, from 1.68 in 2016Q1. The ratio is positive, as 11 funds sold all Dermira Inc shares owned while 21 reduced positions. 35 funds bought stakes while 54 increased positions. They now own 29.11 million shares or 30.57% more from 22.30 million shares in 2016Q1.
Moreover, Cormorant Asset Mgmt Limited Liability has 0.71% invested in Dermira Inc (NASDAQ:DERM) for 172,083 shares. Dekabank Deutsche Girozentrale, a Germany-based fund reported 15,950 shares. Manufacturers Life Insur Company The owns 14,817 shares or 0% of their US portfolio. Rock Springs Limited Partnership accumulated 0.77% or 354,900 shares. Price T Rowe Md holds 0% or 17,347 shares in its portfolio. California State Teachers Retirement reported 44,018 shares or 0% of all its holdings. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Abingworth Llp holds 70,000 shares or 2.14% of its portfolio. Franklin has 505,200 shares for 0.01% of their US portfolio. New Leaf Venture Prtn Ltd Liability Corporation has 196,544 shares for 4.95% of their US portfolio. State Street has 465,835 shares for 0% of their US portfolio. Renaissance Techs Ltd Liability holds 26,000 shares or 0% of its portfolio. Baker Bros Advsrs Ltd Partnership holds 326,428 shares or 0.1% of its portfolio. Point72 Asset Mgmt Lp holds 127,700 shares or 0.03% of its portfolio. Lombard Odier Asset (Usa), a New York-based fund reported 268,878 shares.
Insider Transactions: Since May 2, 2016, the stock had 0 buys, and 17 insider sales for $3.24 million net activity. $225,990 worth of shares were sold by WIGGANS THOMAS G on Monday, May 2. GUGGENHIME ANDREW also sold $301,533 worth of Dermira Inc (NASDAQ:DERM) shares. BAUER EUGENE A had sold 2,500 shares worth $62,725. RINGO WILLIAM R sold $16,825 worth of stock. Shares for $39,116 were sold by Griffith Christopher M..
More recent Dermira Inc (NASDAQ:DERM) news were published by: Marketwatch.com which released: “Dermira Inc. NASDAQ: DERM” on October 03, 2014. Also Investorplace.com published the news titled: “3 Stocks to Watch on Thursday: Ciena Corporation (CIEN), Dermira Inc (DERM …” on June 02, 2016. Streetinsider.com‘s news article titled: “Dermira (DERM) Shares Rise as CIMZIA Phase 3 Met co-Primary Efficacy Endpoints …” with publication date: October 03, 2016 was also an interesting one.
DERM Company Profile
Dermira, Inc., incorporated on August 18, 2010, is a biopharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), in Phase III development for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase III development for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating, and DRM01, in Phase IIb development for the treatment of acne vulgaris, or acne. The Firm is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as psoriasis, hyperhidrosis and acne.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.